Lipids & metabolic liver disease
ApoC-III proteoforms are associated with better lipid, inflammatory, and glucose profiles independent of total apoC-III
Authors' conclusion
While apoC-III is positively associated with biomarkers of cardiometabolic risk, the proportions of three apoC-III proteoforms show opposite associations, independent of total apoC-III concentrations. Measuring not only apoC-III but also the proportions of apoC-III proteoforms can provide valuable information since individuals with similar levels of total apoC-III could display opposite lipid profiles depending on the proportion of apoC-III proteoforms.
Study context
- Population
- Participants from the cross-sectional study of the Di@bet.es cohort; seven apoC-III proteoforms measured by mass spectrometry immunoassay
- Participants
- 875 participants
- Exposure
- ApoC-III proteoform ratios vs total apoC-III
- Outcome
- Associations of seven apoC-III proteoforms with biomarkers of lipid metabolism, inflammation and glucose homeostasis
Methodological detailslinear regression models
- Linear regression models
Main finding
As reported in the abstract
TG: β apoC-III2d; apoC-III2; apoC-III0f
β=−0.173, p < 0.001; β=−0.297, p < 0.001; β=−0.223
p = 0.002
VLDL particle concentration: β apoC-III2d; apoC-III2; apoC-III0f
β=−0.133, p < 0.001; β=−0.265, p < 0.001; β=−0.203
p < 0.001
GlycA: β apoC-III2d; apoC-III2; apoC-III0f
β=−0.148, p < 0.001; β=−0.263, p < 0.001; β=−0.211
p < 0.001
Homeostatic model assessment of insulin resistance (HOMA-IR): β apoC-III2d; apoC-III2; apoC-III0f
β=−0.096, p = 0.003; β=−0.199, p < 0.001; β=−0.114
p = 0.002
Observational data: associations, not effects.
Further findings
Prevalence of cardiometabolic disorders with high levels of these proteoforms
- Lower prevalence of T2D
- P = 0.022
- Lower prevalence of obesity
- P = 0.001
- Lower prevalence of metabolic syndrome
- P = 0.013
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →